8VC founding partner Joe Lonsdale. 8VC led the $12 million Series A investment in Unlearn.AI. Photo by Brian Ach/Getty Images for TechCrunch, under Creative Commons license

Unlearn.AI, a startup that develops software tools meant for clinical research, has announced $12 million in Series A funding led by 8VC, with participation from existing investors including Mubadala Capital Ventures, DCVC, and DCVC Bio. Under the terms of the Series A investment, 8VC Principal Francisco Gimenez has taken a board seat at Unlearn.

The new financing brings the total funding raised by Unlearn since its inception to about $17 million. Unlearn was founded in 2017 by a team of machine learning scientists who sought to build software to assist clinical trials. The company’s current focus is on neurological diseases, starting with Alzheimer’s Disease and Multiple Sclerosis. Unlearn has developed a machine learning platform that helps model and predict progression in clinical trials. The company has begun working closely with biopharmaceutical and medical device companies as well as regulators to ensure its platform delivers while complying with medical and regulatory standards.

Unlearn is still a relatively small startup, with just 16 employees according to LinkedIn data. It’s based out of San Francisco, California.